Current strategies toward safer mu opioid receptor drugs for pain management

References

• Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009 Oct 16;139(2):267–284. PubMed PMID: 19837031; PubMed Central PMCID: PMCPMC2852643.
   PubMed Web of Science ®Google Scholar
• Reuben DB, Alvanzo AA, Ashikaga T, et al. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med. 2015 Feb 17;162(4):295–300. PubMed PMID: 25581341.
   PubMed Web of Science ®Google Scholar
• Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med. 2018 Jan 29;69:451–465. PubMed PMID: 29029586.
   PubMed Web of Science ®Google Scholar
• Bodnar RJ. Endogenous opiates and behavior: 2016. Peptides. 2018 Mar;101:167–212. PubMed PMID: 29366859.
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018 Sep 24. DOI:10.1038/s41386-018-0225-3. PubMed PMID: 30250308.
   PubMed Web of Science ®Google Scholar
• Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018 Aug;19(8):499–514. PubMed PMID: 29934561.
   PubMed Web of Science ®Google Scholar
• Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999 Jan;20(1):19–26. PubMed PMID: 10101958.
   PubMed Web of Science ®Google Scholar
• Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996 Oct 31;383(6603):819–823. PubMed PMID: 8893006.
   PubMed Web of Science ®Google Scholar
• Curbing prescription opioid dependency. Bull World Health Organization. 2017 May 1;95(5):318–319. PubMed PMID: 28479631; PubMed Central PMCID: PMCPMC5418819.
   PubMed Web of Science ®Google Scholar
• Erbs E, Faget L, Scherrer G, et al. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct. 2015 Mar;220(2):677–702. PubMed PMID: 24623156; PubMed Central PMCID: PMCPmc4341027. eng.
   PubMed Web of Science ®Google Scholar
• Pecina M, Karp JF, Mathew S, et al. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2018 Jun 28. DOI:10.1038/s41380-018-0117-2 PubMed PMID: 29955162.
   PubMedGoogle Scholar
• Williams JT, Ingram SL, Henderson G, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013 Jan;65(1):223–254. PubMed PMID: 23321159; PubMed Central PMCID: PMCPMC3565916.
   PubMed Web of Science ®Google Scholar
• Madariaga-Mazon A, Marmolejo-Valencia AF, Li Y, et al. Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics? Drug Discov Today. 2017 Nov;22(11):1719–1729. PubMed PMID: 28743488.
   PubMed Web of Science ®Google Scholar
• Kenakin T. The effective application of biased signaling to new drug discovery. Mol Pharmacol. 2015 Dec;88(6):1055–1061. PubMed PMID: 26138073.
   PubMed Web of Science ®Google Scholar
• Costa-Neto CM, Parreiras ESLT, Bouvier M. A pluridimensional view of biased agonism. Mol Pharmacol. 2016 Nov;90(5):587–595. PubMed PMID: 27638872.
   PubMed Web of Science ®Google Scholar
• Thompson GL, Lane JR, Coudrat T, et al. Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. Biochem Pharmacol. 2016 Aug;1(113):70–87. PubMed PMID: 27286929.
   PubMed Web of Science ®Google Scholar
• Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011 Dec;115(6):1363–1381. PubMed PMID: 22020140; PubMed Central PMCID: PMCPMC3698859.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Schmid CL, Groer CE, et al. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011 Dec;63(4):1001–1019. PubMed PMID: 21873412; PubMed Central PMCID: PMCPMC3186080.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999 Dec 24;286(5449):2495–2498. PubMed PMID: 10617462.
   PubMed Web of Science ®Google Scholar
• Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017 Nov 16;171(5):1165–1175 e13. PubMed PMID: 29149605; PubMed Central PMCID: PMCPMC5731250.
   PubMed Web of Science ®Google Scholar
• Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. 2018 Jan 5. DOI:10.1038/nrd.2017.229 PubMed PMID: 29302067.
   Web of Science ®Google Scholar
• Keith DE, Murray SR, Zaki PA, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996 Aug 9;271(32):19021–19024. PubMed PMID: 8702570.
   PubMed Web of Science ®Google Scholar
• Pradhan AA, Smith ML, Kieffer BL, et al. Ligand-directed signalling within the opioid receptor family. Br J Pharmacol. 2012 Nov;167(5):960–969. PubMed PMID: 22708627; PubMed Central PMCID: PMCPMC3492979.
   PubMed Web of Science ®Google Scholar
• McPherson J, Rivero G, Baptist M, et al. mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol. 2010 Oct;78(4):756–766. PubMed PMID: 20647394; PubMed Central PMCID: PMCPMC2981392.
   PubMed Web of Science ®Google Scholar
• Butler S. Buprenorphine-Clinically useful but often misunderstood. Scand J Pain. 2013 Jul 1;4(3):148–152. PubMed PMID: 29913911.
   PubMedGoogle Scholar
• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018 Jul 26. DOI:10.1007/s40265-018-0953-z PubMed PMID: 30051169.
   PubMed Web of Science ®Google Scholar
• Fishman MA, Kim PS. Buprenorphine for chronic pain: a systemic review. Curr Pain Headache Rep. 2018 Oct 5;22(12):83. PubMed PMID: 30291571.
   PubMed Web of Science ®Google Scholar
• Hale M, Urdaneta V, Kirby MT, et al. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–240. PubMed PMID: 28182123; PubMed Central PMCID: PMCPMC5279817.
   PubMed Web of Science ®Google Scholar
• Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Res. 2014;7:495–503. PubMed PMID: 25170278; PubMed Central PMCID: PMCPMC4145844.
   PubMed Web of Science ®Google Scholar
• Ehrlich AT, Darcq E. Recommending buprenorphine for pain management. Pain Manag. 2019 Jan 1;9(1):13–16. PubMed PMID: 30507294.
   PubMed Web of Science ®Google Scholar
• Vlok R, An GH, Binks M, et al. Sublingual buprenorphine versus intravenous or intramuscular morphine in acute pain: A systematic review and meta-analysis of randomized control trials. Am J Emerg Med. 2018 May 24. DOI:10.1016/j.ajem.2018.05.052 PubMed PMID: 29857944.
   Web of Science ®Google Scholar
• Valdes LJ 3rd, Diaz JL, Paul AG. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J Ethnopharmacol. 1983 May;7(3):287–312. PubMed PMID: 6876852.
   PubMed Web of Science ®Google Scholar
• Marmolejo-Valencia AF, Martinez-Mayorga K. Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist. J Comput Aided Mol Des. 2017 May;31(5):467–482. PubMed PMID: 28364251.
   PubMed Web of Science ®Google Scholar
• Harding WW, Tidgewell K, Byrd N, et al. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem. 2005 Jul 28;48(15):4765–4771. PubMed PMID: 16033256.
   PubMed Web of Science ®Google Scholar
• Butelman ER, Rus S, Simpson DS, et al. The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates. J Pharmacol Exp Ther. 2008 Oct;327(1):154–160. PubMed PMID: 18593955; PubMed Central PMCID: PMCPMC2614932.
   PubMed Web of Science ®Google Scholar
• Lamb K, Tidgewell K, Simpson DS, et al. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012 Mar 1;121(3):181–188. PubMed PMID: 22119134; PubMed Central PMCID: PMCPMC3288203.
   PubMed Web of Science ®Google Scholar
• Groer CE, Tidgewell K, Moyer RA, et al. An opioid agonist that does not induce mu-opioid receptor–arrestin interactions or receptor internalization. Mol Pharmacol. 2007 Feb;71(2):549–557. PubMed PMID: 17090705; PubMed Central PMCID: PMCPMC3926195.
   PubMed Web of Science ®Google Scholar
• Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988 May-Jun;23(1):115–119. PubMed PMID: 3419199.
   PubMed Web of Science ®Google Scholar
• Varadi A, Marrone GF, Palmer TC, et al. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2. J Med Chem. 2016 Sep 22;59(18):8381–8397. PubMed PMID: 27556704; PubMed Central PMCID: PMCPMC5344672.
   PubMed Web of Science ®Google Scholar
• Silva CN, Nunes KP, Torres FS, et al. PnPP-19, a synthetic and nontoxic peptide designed from a phoneutria nigriventer toxin, potentiates erectile function via NO/cGMP. J Urol. 2015 Nov;194(5):1481–1490. PubMed PMID: 26119670.
   PubMed Web of Science ®Google Scholar
• Freitas AC, Pacheco DF, Machado MF, et al. PnPP-19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidase. Br J Pharmacol. 2016 May;173(9):1491–1501. PubMed PMID: 26947933; PubMed Central PMCID: PMCPMC4831307.
   PubMed Web of Science ®Google Scholar
• Freitas ACN, Peigneur S, Macedo FHP, et al. The peptide PnPP-19, a spider toxin derivative, activates mu-opioid receptors and modulates calcium channels. Toxins (Basel). 2018 Jan 15;10(1). DOI:10.3390/toxins10010043 PubMed PMID: 29342943; PubMed Central PMCID: PMCPMC5793130.
   Web of Science ®Google Scholar
• Durkin B, Page C, Glass P. Pregabalin for the treatment of postsurgical pain. Expert Opin Pharmacother. 2010 Nov;11(16):2751–2758. PubMed PMID: 20977407.
   PubMed Web of Science ®Google Scholar
• Chan HCS, McCarthy D, Li J, et al. Designing safer analgesics via mu-opioid receptor pathways. Trends Pharmacol Sci. 2017 Nov;38(11):1016–1037. PubMed PMID: 28935293; PubMed Central PMCID: PMCPMC5690544.
   PubMed Web of Science ®Google Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708–717. PubMed PMID: 23300227.
   PubMed Web of Science ®Google Scholar
• Altarifi AA, David B, Muchhala KH, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017 Jun;31(6):730–739. PubMed PMID: 28142305; PubMed Central PMCID: PMCPMC5646680.
   PubMed Web of Science ®Google Scholar
• Negus SS, Freeman KB. Abuse potential of biased Mu opioid receptor agonists. Trends Pharmacol Sci. 2018 Nov;39(11):916–919. PubMed PMID: 30343727.
   PubMed Web of Science ®Google Scholar
• Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413–2424. PubMed PMID: 29062240; PubMed Central PMCID: PMCPMC5638571.
   PubMed Web of Science ®Google Scholar
• Kieffer BL. Drug discovery: designing the ideal opioid. Nature. 2016 Sep 08;537(7619):170–171. PubMed PMID: 27533037.
   PubMed Web of Science ®Google Scholar
• Manglik A, Kruse AC, Kobilka TS, et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature. 2012 Mar 21;485(7398):321–326. PubMed PMID: 22437502; PubMed Central PMCID: PMCPMC3523197.
   PubMed Web of Science ®Google Scholar
• Manglik A, Lin H, Aryal DK, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016 Sep 8;537(7619):185–190. PubMed PMID: 27533032; PubMed Central PMCID: PMCPMC5161585.
   PubMed Web of Science ®Google Scholar
• Hill R, Disney A, Conibear A, et al. The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol. 2018 Jul;175(13):2653–2661. PubMed PMID: 29582414; PubMed Central PMCID: PMCPMC6003631.
   PubMed Web of Science ®Google Scholar
• Stein C, Machelska H. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev. 2011 Dec;63(4):860–881. PubMed PMID: 21969325.
   PubMed Web of Science ®Google Scholar
• Badiani A, Belin D, Epstein D, et al. Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci. 2011 Oct 5;12(11):685–700. PubMed PMID: 21971065; PubMed Central PMCID: PMCPMC3721140.
   PubMed Web of Science ®Google Scholar
• Stein C. Opioid Receptors. Annu Rev Med. 2016;67:433–451. PubMed PMID: 26332001.
   PubMed Web of Science ®Google Scholar
• Lacy BE. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Oct;48(8):817–830. PubMed PMID: 30194692.
   PubMed Web of Science ®Google Scholar
• Chung C, Carteret AF, McKelvy AD, et al. Analgesic properties of loperamide differ following systemic and local administration to rats after spinal nerve injury. Eur J Pain. 2012 Aug;16(7):1021–1032. PubMed PMID: 22508374; PubMed Central PMCID: PMCPMC3389202.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez S, Quadir MA, Gupta S, et al. Polyglycerol-opioid conjugate produces analgesia devoid of side effects. Elife. 2017 Jul 4;6. DOI:10.7554/eLife.27081 PubMed PMID: 28673386; PubMed Central PMCID: PMCPMC5496737.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Labuz D, et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science. 2017 Mar 3;355(6328):966–969. PubMed PMID: 28254944.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gaztelumendi A, Spahn V, Labuz D, et al. Analgesic effects of a novel pH-dependent mu-opioid receptor agonist in models of neuropathic and abdominal pain. Pain. 2018 Nov;159(11):2277–2284. PubMed PMID: 29994988.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Rodriguez-Gaztelumendi A, et al. Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist. Sci Rep. 2018 Jun 12;8(1):8965. PubMed PMID: 29895890; PubMed Central PMCID: PMCPMC5997768.
   PubMedGoogle Scholar
• Fujita W, Gomes I, Devi LA. Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015 Jan;172(2):375–387. PubMed PMID: 24571499; PubMed Central PMCID: PMCPMC4292954.
   PubMed Web of Science ®Google Scholar
• Gomes I, Ayoub MA, Fujita W, et al. G protein-coupled receptor heteromers. Annu Rev Pharmacol Toxicol. 2016;56:403–425. PubMed PMID: 26514203; PubMed Central PMCID: PMCPMC5147582.
   PubMed Web of Science ®Google Scholar
• Massotte D. In vivo opioid receptor heteromerization: where do we stand? Br J Pharmacol. 2015 Jan;172(2):420–434. PubMed PMID: 24666391; PubMed Central PMCID: PMCPMC4292957.
   PubMed Web of Science ®Google Scholar
• Aceto MD, Harris LS, Negus SS, et al. MDAN-21: a bivalent opioid ligand containing mu-agonist and delta-antagonist pharmacophores and its effects in rhesus monkeys. Int J Med Chem. 2012;2012:327257. PubMed PMID: 25954526; PubMed Central PMCID: PMCPMC4412046.
   PubMedGoogle Scholar
• Fujita W, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448–456. PubMed PMID: 25261794; PubMed Central PMCID: PMCPMC4769596.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Laterza L, Ianiro G, et al. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2016 Jul;17(10):1395–1402. PubMed PMID: 27267380.
   PubMed Web of Science ®Google Scholar
• Wang D, Tawfik VL, Corder G, et al. Functional divergence of delta and mu opioid receptor organization in CNS pain circuits. Neuron. 2018 Apr 4;98(1):90–108 e5. PubMed PMID: 29576387; PubMed Central PMCID: PMCPMC5896237.
   PubMed Web of Science ®Google Scholar
• Akgun E, Javed MI, Lunzer MM, et al. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11595–11599. PubMed PMID: 23798416; PubMed Central PMCID: PMCPMC3710855.
   PubMedGoogle Scholar
• Peterson CD, Kitto KF, Akgun E, et al. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice. Pain. 2017 Dec;158(12):2431–2441. PubMed PMID: 28891868; PubMed Central PMCID: PMCPMC5790118.
   PubMed Web of Science ®Google Scholar
• Khroyan TV, Polgar WE, Cami-Kobeci G, et al. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-meth oxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward. J Pharmacol Exp Ther. 2011 Mar;336(3):952–961. PubMed PMID: 21177476; PubMed Central PMCID: PMCPMC3061529.
   PubMed Web of Science ®Google Scholar
• Li JX. Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10225–10227. PubMed PMID: 27573851; PubMed Central PMCID: PMCPMC5027450.
   PubMed Web of Science ®Google Scholar
• Ding H, Czoty PW, Kiguchi N, et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5511–8. PubMed PMID: 27573832; PubMed Central PMCID: PMCPMC5027459.
   PubMed Web of Science ®Google Scholar
• Livingston KE, Traynor JR. Allostery at opioid receptors: modulation with small molecule ligands. Br J Pharmacol. 2018 Jul;175(14):2846–2856. PubMed PMID: 28419415; PubMed Central PMCID: PMCPMC6016636.
   PubMed Web of Science ®Google Scholar
• Remesic M, Hruby VJ, Porreca F, et al. Recent advances in the realm of allosteric modulators for opioid receptors for future therapeutics. ACS Chem Neurosci. 2017 Jun 21;8(6):1147–1158. PubMed PMID: 28368571; PubMed Central PMCID: PMCPMC5689070.
   PubMed Web of Science ®Google Scholar
• Stein C. New concepts in opioid analgesia. Expert Opin Investig Drugs. 2018 Oct;27(10):765–775. PubMed PMID: 30148648.
   PubMed Web of Science ®Google Scholar
• Burford NT, Clark MJ, Wehrman TS, et al. Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor. Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10830–10835. PubMed PMID: 23754417; PubMed Central PMCID: PMCPMC3696790.
   PubMed Web of Science ®Google Scholar
• Livingston KE, Stanczyk MA, Burford NT, et al. Pharmacologic evidence for a putative conserved allosteric site on opioid receptors. Mol Pharmacol. 2018 Feb;93(2):157–167. PubMed PMID: 29233847; PubMed Central PMCID: PMCPMC5767684.
   PubMed Web of Science ®Google Scholar
• Olson KM, Lei W, Keresztes A, et al. Novel molecular strategies and targets for opioid drug discovery for the treatment of chronic pain. Yale J Biol Med. 2017 Mar;90(1):97–110. PubMed PMID: 28356897; PubMed Central PMCID: PMCPMC5369049.
   PubMedGoogle Scholar
• Noble F, Roques BP. Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin Ther Targets. 2007 Feb;11(2):145–159. PubMed PMID: 17227231.
   PubMed Web of Science ®Google Scholar
• Roques BP, Fournie-Zaluski MC, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. 2012 Apr;11(4):292–310. PubMed PMID: 22460123.
   PubMed Web of Science ®Google Scholar
• Livingston KE, Mahoney JP, Manglik A, et al. Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. Elife. 2018 Jun 22;7. DOI:10.7554/eLife.32499 PubMed PMID: 29932421; PubMed Central PMCID: PMCPMC6042960.
   PubMed Web of Science ®Google Scholar
• Stoeber M, Jullie D, Lobingier BT, et al. A genetically encoded biosensor reveals location bias of opioid drug action. Neuron. 2018 Jun 6;98(5):963–976 e5. PubMed PMID: 29754753.
   PubMed Web of Science ®Google Scholar
• Urs NM, Gee SM, Pack TF, et al. Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8178–E8186. PubMed PMID: 27911814; PubMed Central PMCID: PMCPMC5167191.
   PubMed Web of Science ®Google Scholar
• Marcott PF, Gong S, Donthamsetti P, et al. Regional heterogeneity of D2-receptor signaling in the dorsal striatum and nucleus accumbens. Neuron. 2018 May 2;98(3):575–587 e4. PubMed PMID: 29656874; PubMed Central PMCID: PMCPMC6048973.
   PubMed Web of Science ®Google Scholar
• Stein C. Targeting pain and inflammation by peripherally acting opioids. Front Pharmacol. 2013;4:123. PubMed PMID: 24068999; PubMed Central PMCID: PMCPMC3779927.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Gainetdinov RR, Sotnikova TD, et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci. 2003 Nov 12;23(32):10265–10273. PubMed PMID: 14614085.
   PubMed Web of Science ®Google Scholar
• Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992 Feb;12(2):483–488. PubMed PMID: 1346804.
   PubMed Web of Science ®Google Scholar
• Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191–225. PubMed PMID: 2648975.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018 May 15;134(Pt A):108–120. PubMed PMID: 28830758.
   PubMedGoogle Scholar
• Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016 Jun 1;138(21):6754–6764. PubMed PMID: 27192616; PubMed Central PMCID: PMCPMC5189718.
   PubMed Web of Science ®Google Scholar
• Da Fonseca Pacheco D, Freitas AC, Pimenta AM, et al. A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems. J Venom Anim Toxins Incl Trop Dis. 2016;22:34. PubMed PMID: 28031732; PubMed Central PMCID: PMCPMC5175391.
   PubMed Web of Science ®Google Scholar
• Liang DY, Li WW, Nwaneshiudu C, et al. Pharmacological characters of oliceridine, a mu-opioid receptor G-protein[FIGURE DASH]biased ligand in mice. Anesth Analg. 2018 Jul 21. DOI:10.1213/ANE.0000000000003662 PubMed PMID: 30044299.
   Google Scholar
• Gomes I, Fujita W, Gupta A, et al. Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12072–12077. PubMed PMID: 23818586; PubMed Central PMCID: PMCPMC3718106.
   PubMed Web of Science ®Google Scholar
• Portoghese PS, Akgun E, Lunzer MM. Heteromer induction: an approach to unique pharmacology? ACS Chem Neurosci. 2017 Mar 15;8(3):426–428. PubMed PMID: 28139906.
   PubMed Web of Science ®Google Scholar
• Daniels DJ, Lenard NR, Etienne CL, et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19208–19213. PubMed PMID: 16365317; PubMed Central PMCID: PMCPMC1323165.
   PubMed Web of Science ®Google Scholar
• Burford NT, Livingston KE, Canals M, et al. Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the delta-opioid receptor. J Med Chem. 2015 May 28;58(10):4220–4229. PubMed PMID: 25901762; PubMed Central PMCID: PMCPMC4703104.
   PubMed Web of Science ®Google Scholar